Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: Phil Cressman who wrote (26)	1/13/1999 12:06:00 AM
From: Robert Parker	Respond to of 255

Phil, The device I was using was desk bound and about the size of a loaf of bread. Not at all portable, but if it was the only thing that ever got to market and had to be kept at home, it would cut my daily injections by more than half. Fortunately they told me that they had prototypes down to a portable size and don't intend to try market anything larger. I am guessing (by the way I'm not based in the US) that this product would be marketed at a subsidised price. Especially if there is competition product. Glucometers are very regularly given away. The money is in the test strips. I got my injection pen for free so I would use a specific insulin cartridge. Given ARDM is teamed with the insulin supplier Novo Nordisk I would expect the profit streams to come from 'special' insulin cartridges. Even if the device is expensive, health funds may pick it up. I talk to many fellow diabetics who no very little about advances in technology, but they all get excited about not having to stick themselves. While many get away with 2, I have 5 injections a day, by choice, because the latest insulins can be very effective for intensive management and provide the ability to vary your diet and freedom considerably. This was totally unheard of 5 years ago. I can't see any insulin dependent diabetic not getting such a product in time. There are about 1 million type 1 diabetics in the US, all requiring insulin by injection. The sad thing is the peak age for aquiring type 1 is 10-14 years of age parents would mortgage the house to avoid having to get their children to use needles. There is no cure. Their are 10 times as many type 2 and many of them also require injections. A large factor in people who have symptoms is knowing what the treatment involves. Here's a spot for the stats... diabetes.org Maybe that was too long an answer....I've got to remember this sites about stocks! There are a lot of myths among the healthy so it doesn't surprise me the potential of a successful product isn't fully appreciated. What will be the difference between this being a good stock and a great stock is whether their patents allow them to produce a standalone product or there are mulitple devices with similar results.